VRCDF 0.14 Verici Dx plc
| Range: | 0.08496-0.2 | Vol Avg: | 161 | Last Div: | 0 | Changes: | -0.03 |
| Beta: | 1.53 | Cap: | 0.02B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Fri May 27 2022 | Empoloyees: | 14 | ||
| CUSIP: | CIK: | ISIN: | GB00BM8HZD43 | Country: | GB | ||
| CEO: | Ms. Sara jane Barrington A.C.A., A.C.I.M. | Website: | https://www.vericidx.com | ||||
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow